KDR: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of KDR. The page also collects GeneMedi's different modalities and formats products for KDR in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the KDR target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009]

Pre-made KDR-specific INN-index biosimilar (antibody&conjugates)-Vulinacimab, Olinvacimab, Ramucirumab, Pulocimab, alacizumab pegol, pegdinetanib, Alacizumab, Tanibirumab

Anti-KDR therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.	Products Name (INN Index)	INN Name	Previous Name	Target	Format	Order
GMP-Bios-ab-632	Pre-Made Vulinacimab biosimilar, Whole mAb, Anti-VEGFR2/KDR Antibody: Anti-CD309/FLK1/VEGFR therapeutic antibody	Vulinacimab		VEGFR2/KDR	Whole mAb
GMP-Bios-ab-396	Pre-Made Olinvacimab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody	Olinvacimab	Tanibirumab	KDR	Whole mAb
GMP-Bios-ab-468	Pre-Made Ramucirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody	Ramucirumab		KDR	Whole mAb
GMP-Bios-ab-687	Pre-Made Pulocimab biosimilar, Whole mAb, Anti-VEGFR2/KDR Antibody: Anti-CD309/FLK1/VEGFR therapeutic antibody	Pulocimab		VEGFR2/KDR	Whole mAb
GMP-Bios-INN-723		alacizumab pegol		KDR	pegylated
GMP-Bios-INN-950		pegdinetanib		KDR	pegylated
GMP-Bios-ab-014	Pre-Made Alacizumab biosimilar, di-Fab, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody	Alacizumab		KDR	di-Fab
GMP-Bios-ab-550	Pre-Made Tanibirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody	Tanibirumab	olinvacimab	KDR	Whole mAb

Pre-made anti-KDR inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-KDR benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-KDR mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.	Antibody Name	Format	Classified by tag	Order
GM-Tg-hg-T80975-Ab	Anti-KDR monoclonal antibody	mab	Biofunctional antibody, Therapeutics Target antibody, Cytokine antibody